Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-05-17
2005-05-17
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S231000, C544S234000, C544S237000
Reexamination Certificate
active
06894048
ABSTRACT:
Substituted dihydrophthalazine sulfur containing compositions are provided which are active as non-NMDA ionotropic excitatory amino acid (EAA) receptor antagonists. The compositions are useful for treating disorders associated with excessive activation of the non-NMDA subtype of the ionotropic EAA receptor. The compounds further are useful as testing agents to identify and characterize other compounds for the treatment of these disorders. The compounds are useful therapeutically as sedatives or for the treatment of neuropsychopharmacological disorders such as stroke, ischemia and epilepsy. The compositions may be provided in combination with a suitable carrier for oral or parenteral administration. The compounds may be administered orally or parenterally for the treatment of a variety of disorders associated with non-NMDA EEA receptor function.
REFERENCES:
patent: 5716956 (1998-02-01), Pelletier
patent: 6048853 (2000-04-01), Collins et al.
patent: 6329370 (2001-12-01), Napoletano et al.
patent: 196 17 863 (1997-10-01), None
patent: WO 9640646 (1996-12-01), None
Ikonomidou et al. Critical Reviews in Neurobiology, vol. 10(2), p. 239-263 (1996).*
Chen, et al., “Evaluation of five methods for testing anticonvulsant activities,”Proc. Soc. Exp. Biol. Med.87: 334-339 (1954).
Hussy, et al., “Functional properties of cloned 5-hydroxytryplamine ionotropic receptor subunit: comparison with native mouse receptors,”J. Physiol.(Lond.) 481(2): 311-323 (1994).
Le Peillet, et al., “The non-NDMA antagonists, NBOX and GYKI 52466, protect against cortical and striatai cell loss following transient global ischaemia in the rat,”Brain Res.571: 115-120 (1992).
Lipton & Rosenberg, “Excitatory amino acids as a final common pathway for neurologic disorders,”N. Engl. J. Med.330: 613-622 (1994).
McBurney, “Therapeutic potential of NMDA antagonists in neurodegenerative diseases,”Neurobiol. Aging15: 271-273 (1994).
Meldrum, “Excitatory amino acids in epilepsy and potential novel therapies,”Epilepsy Res.12: 189-196 (1992).
Remington's Pharmaceutical Sciences, 17thed., p. 1418 (1985).
Smith & Meldrum, “Cerebroprotective effect of a non-N-methyl-O-aspartate antagonist, GYKI 52466, after focal ischemia in the rat,”Stroke23: 861-864 (!992).
Tarnawa, et al., “Electrophysiological studies with a 2,3-benzodiazepine muscle relaxant: GYKI 52466,”Eur. J. Pharmacol.167: 193-199 (1989).
Yamaguchi, et al., “Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYK! 52466 and NBOX in maximal electroshock and chemoconvulsant seizure models,”Epilepsy Res.15: 179-184 (1993).
Li Baoqing
Maccecchini Maria-Luisa
Pei Xue-Feng
Licata & Tyrrell P.C.
Raymond Richard L.
Transgenomic Inc.
LandOfFree
Sulfur containing dihydrophthalazine antagonists of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sulfur containing dihydrophthalazine antagonists of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfur containing dihydrophthalazine antagonists of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3377842